PHLOW CORPORATION lobbying for PHLOW CORPORATION

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$420,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Virginia

Official filing document

Government bodies contacted 7

Defense, Dept of (DOD)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Natl Economic Council (NEC)
Natl Security Council (NSC)
Office of Management & Budget (OMB)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 9

HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 4016
Department of Defense Appropriations Act, 2026
S 2572
Department of Defense Appropriations Act, 2026
S 2296
National Defense Authorization Act for Fiscal Year 2026
S 4638
National Defense Authorization Act for Fiscal Year 2025
S 1784
MAPS Act
S 2062
RAPID Reserve Act
HR 3966
Improving Atmospheric River Forecasts Act

Lobbying activity 3

Budget/Appropriations

FY26 Labor, Health and Human Services, Education, and Related Agencies Appropriations (H.R. 5304/S.2587) FY26 Department of Defense Appropriations (H.R. 4016/S.2572/S.2296/S.4638)

Health Issues

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Manufacturing

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)